Latest Balance Sheet News

QuickFee Limited reports a 9% revenue increase in Q1 FY26 alongside a strategic US Pay Now business sale and a proposed A$28.4 million capital return to shareholders.

Cann Group Limited reported a near break-even net operating cash flow for Q1 FY2026 and achieved its first EBITDA-positive month, setting the stage for a major debt restructure that will significantly reduce its borrowings.

Morella Corporation’s September quarter report reveals significant progress in its diversified critical minerals portfolio, including new titanium-vanadium exposure and streamlined US lithium assets. The company is gearing up for drilling and resource definition in 2026, supported by strengthened funding.

Activeport Group Ltd reported steady Q1 FY26 results with key project deliveries and a successful capital raise, positioning the company for accelerated growth across Asia and beyond.

Viridis Mining and Minerals has delivered a landmark Pre-Feasibility Study for its Colossus Rare Earth Project, confirming robust economics and securing key strategic funding and land expansions in Brazil.

FlexiRoam Limited has reported its strongest quarterly operating cash flow ever, signalling a successful business reset and setting the stage for growth with a new AI-assisted connectivity platform.

AdNeo Limited reports a robust 54% increase in customer receipts for Q1 FY26, driven by the strategic acquisition of Learnt Group and significant cost synergies. The company also slashes debt and advances its sales pipeline, positioning itself for cash flow positivity within the year.

Austral Resources Australia Ltd reported robust Q3 2025 copper production and secured $40 million in new capital, setting the stage for accelerated growth and ASX reinstatement.

Smart Parking Limited reports a record FY25 with revenues up 42% to $77.2 million, driven by organic growth and strategic acquisitions including Peak Parking in the US. The company targets 3,000 managed sites by 2028, leveraging proprietary AI technology across multiple international markets.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.

Challenger Limited has welcomed APRA’s proposed capital standards for longevity products, highlighting their potential to reduce capital requirements and stimulate growth in Australia’s retirement income sector.

Mont Royal Resources has completed a transformative merger with Commerce Resources, securing A$10 million to advance the Ashram Rare Earths Project, positioning itself as a key player in North America’s critical minerals sector.